[
  {
    "ts": "2025-09-26T20:51:00+00:00",
    "headline": "Eli Lilly, Pfizer, Amgen Stocks Rise After Trump’s 100% Pharma Tariff Threat. Here’s Why.",
    "summary": "Trump’s threat of a 100% tariff on imported branded or patented drugs sounds dramatic, yet, pharma stocks were mostly in the green as the past few months have already seen a flurry of companies announcing plans to invest in the U.S.",
    "url": "https://www.barrons.com/articles/eli-lilly-pfizer-stock-trump-pharma-tariffs-2b9ddfb7?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "56f949c4-0da7-3f93-bd14-99e92ada288d",
      "content": {
        "id": "56f949c4-0da7-3f93-bd14-99e92ada288d",
        "contentType": "STORY",
        "title": "Eli Lilly, Pfizer, Amgen Stocks Rise After Trump’s 100% Pharma Tariff Threat. Here’s Why.",
        "description": "",
        "summary": "Trump’s threat of a 100% tariff on imported branded or patented drugs sounds dramatic, yet, pharma stocks were mostly in the green as the past few months have already seen a flurry of companies announcing plans to invest in the U.S.",
        "pubDate": "2025-09-26T20:51:00Z",
        "displayTime": "2025-09-26T20:51:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/56f949c4-0da7-3f93-bd14-99e92ada288d/eli-lilly-pfizer-amgen.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/9c4dcca7884950e3db5db96665566e4f",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/83u1lWi1Gmyp.RPyQnAUbA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/9c4dcca7884950e3db5db96665566e4f.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VdW5e_D92WAkn9.oSuD4DA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/9c4dcca7884950e3db5db96665566e4f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/eli-lilly-pfizer-stock-trump-pharma-tariffs-2b9ddfb7?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-26T15:45:00+00:00",
    "headline": "Has AbbVie Successfully Navigated Top-line Growth Post Humira LOE?",
    "summary": "ABBV eyes a 2025 rebound as Skyrizi and Rinvoq drive growth beyond Humira, with oncology and neuroscience adding momentum.",
    "url": "https://finance.yahoo.com/news/abbvie-successfully-navigated-top-line-154500229.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "43ee2eab-9ef3-3587-91fb-023938183968",
      "content": {
        "id": "43ee2eab-9ef3-3587-91fb-023938183968",
        "contentType": "STORY",
        "title": "Has AbbVie Successfully Navigated Top-line Growth Post Humira LOE?",
        "description": "",
        "summary": "ABBV eyes a 2025 rebound as Skyrizi and Rinvoq drive growth beyond Humira, with oncology and neuroscience adding momentum.",
        "pubDate": "2025-09-26T15:45:00Z",
        "displayTime": "2025-09-26T15:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/dbd916198e87314e1ef238f8179e6227",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OQG3.5Wd9P9R69q2rhm9rA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/dbd916198e87314e1ef238f8179e6227.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pBlncPVBhEXpjxtBDlEOsg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/dbd916198e87314e1ef238f8179e6227.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-successfully-navigated-top-line-154500229.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-successfully-navigated-top-line-154500229.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-26T12:45:00+00:00",
    "headline": "AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease",
    "summary": "AbbVie (NYSE: ABBV) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tavapadon, a novel selective dopamine D1/D5 receptor partial agonist that was studied as a once daily oral treatment for Parkinson's disease.",
    "url": "https://finance.yahoo.com/news/abbvie-submits-drug-application-u-124500442.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "101c7637-7322-394e-b3fa-0b86e062dd29",
      "content": {
        "id": "101c7637-7322-394e-b3fa-0b86e062dd29",
        "contentType": "STORY",
        "title": "AbbVie Submits New Drug Application to U.S. FDA for Tavapadon for the Treatment of Parkinson's Disease",
        "description": "",
        "summary": "AbbVie (NYSE: ABBV) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tavapadon, a novel selective dopamine D1/D5 receptor partial agonist that was studied as a once daily oral treatment for Parkinson's disease.",
        "pubDate": "2025-09-26T12:45:00Z",
        "displayTime": "2025-09-26T12:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/a5eaa0af5f515703fe951de405417559",
          "originalWidth": 400,
          "originalHeight": 70,
          "caption": "AbbVie logo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g0d6LyVLzKGBfCQ5BSCPww--~B/aD03MDt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/a5eaa0af5f515703fe951de405417559.cf.webp",
              "width": 400,
              "height": 70,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IUj902SDWZLhwmCbmJBNXA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/a5eaa0af5f515703fe951de405417559.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-submits-drug-application-u-124500442.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-submits-drug-application-u-124500442.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]